10-Q: IDEAYA Biosciences and Gilead Sciences Expand Collaboration to Evaluate IDE397 in Combination with Trodelvy in NSCLC

IDEAYA Biosciences and Gilead Sciences expand their collaboration to evaluate IDE397 in combination with Trodelvy in MTAP-deletion NSCLC, alongside a financial update in a recent 10-Q filing.

Summary

• IDEAYA Biosciences, Inc. has filed its quarterly report on Form 10-Q, detailing its financial performance and business activities for the period ended March 31, 2025.
• The company is focused on precision medicine oncology, developing targeted therapeutics using molecular diagnostics.
• IDEAYA is advancing its clinical pipeline, which includes darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase).
• A key highlight is the expansion of the clinical study collaboration with Gilead Sciences to evaluate IDE397 in combination with Trodelvy in MTAP-deletion NSCLC.
• IDEAYA reported cash, cash equivalents, and marketable securities of approximately $1.05 billion as of March 31, 2025.
• The company incurred a net loss of $72.2 million for the quarter ended March 31, 2025, compared to a net loss of $39.6 million for the same period in 2024.
• Research and development expenses increased to $70.9 million from $42.8 million year-over-year, driven by clinical trial and manufacturing costs.
• General and administrative expenses also increased to $13.5 million from $8.2 million year-over-year, due to personnel and consulting costs.
• IDEAYA is targeting an IND submission to the FDA in the second half of 2025 for IDE034, a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program.
• IDEAYA is also targeting an IND submission to the FDA in the second half of 2025 for IDE574, a potential first-in-class KAT6/7 dual inhibitor program.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company has a strong cash position and is making progress in its clinical programs, it is also experiencing significant losses and increased operating expenses. The expansion of the collaboration with Gilead is a positive sign, but the overall financial picture is somewhat concerning.

Positives

• IDEAYA has a strong cash position with approximately $1.05 billion in cash, cash equivalents, and marketable securities as of March 31, 2025.
• The expansion of the collaboration with Gilead Sciences indicates confidence in IDEAYA's IDE397 and its potential in combination therapies.
• The company is actively advancing its pipeline with multiple IND submissions targeted for the second half of 2025.
• FDA granted Breakthrough Therapy designation (BTD) for darovasertib, a potential first-in-class protein kinase C (PKC) inhibitor, for the neoadjuvant treatment of adult patients with primary uveal melanoma (UM) for whom enucleation has been recommended.

Negatives

• IDEAYA incurred a significant net loss of $72.2 million for the quarter ended March 31, 2025, which is an increase from the $39.6 million loss in the same period of 2024.
• The company has an accumulated deficit of $695.0 million as of March 31, 2025.
• The company has not generated any revenue from commercial products since inception.

Risks

• The company's prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry.
• The company may require additional funds to commercialize its products.
• There can be no assurance that the Companys research and development will be successfully completed, that adequate protection for the Companys intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable.
• Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Companys ability to achieve its intended business objectives.

Future Outlook

The company expects operating losses to continue and increase for the foreseeable future, as the Company progresses clinical development activities for its lead product candidates.

Management Comments

• Management believes that the Companys current cash, cash equivalents and marketable securities will be sufficient to fund its planned operations for at least 12 months from the date of the issuance of these financial statements.

Industry Context

The company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations.

Comparison to Industry Standards

• It is difficult to compare IDEAYA's results directly to industry standards without knowing the specific details of their clinical programs and collaborations.
• However, the company's cash position of $1.05 billion is relatively strong compared to other early-stage biotech companies, providing them with a significant runway to fund their operations.
• The increase in R&D expenses is also typical for companies in this stage, as they invest heavily in clinical trials and drug development.
• The company's collaborations with major pharmaceutical companies like Gilead, Merck, and Pfizer are also a positive sign, as these partnerships provide access to resources and expertise that can accelerate the development of their product candidates.
• Some comparable companies in the precision medicine oncology space include Relay Therapeutics, Black Diamond Therapeutics, and Blueprint Medicines, but their financial situations and clinical programs may vary significantly.

Management Changes

Stakeholder Impact

• Shareholders: The increased net loss may be a concern for shareholders, but the strong cash position and pipeline progress are positive.
• Employees: The company is expanding its workforce to support its growth, which is a positive sign for employees.
• Patients: The company is developing new therapies for various cancers, which could benefit patients in the future.
• Collaboration Partners: The company is actively collaborating with major pharmaceutical companies, which could lead to new opportunities and revenue streams.

Next Steps

• IDEAYA is targeting an IND submission to the FDA in the second half of 2025 for IDE034, a potential first-in-class B7H3/PTK7 topoisomerase-I-inhibitor-payload BsADC program.
• IDEAYA is also targeting an IND submission to the FDA in the second half of 2025 for IDE574, a potential first-in-class KAT6/7 dual inhibitor program.
• Commencement of the Phase 3 registration-enabling trial for darovasertib in neoadjuvant UM is targeted for the first half of 2025.
• IDEAYA is targeting a median progression free survival, or PFS, readout for the Phase 2/3 registration-enabling trial of the darovasertib and crizotinib combination in 1L HLA-A2(-) MUM by year-end 2025.
• IDEAYA is targeting a median overall survival, or OS, readout from our Phase 2 clinical trial, designated as IDE196-001, in over 40 1L MUM patients at a medical conference in the second half of 2025.
• IDEAYA is targeting to enable our wholly-owned clinical combination of IDE397 and IDE892, our potential best-in-class MTA-cooperative PRMT5 inhibitor development candidate, in the second half of 2025 in MTAP-deletion NSCLC.

Key Dates

Keywords

IDEAYA Biosciences, Gilead Sciences, IDE397, Trodelvy, MTAP-deletion, NSCLC, Darovasertib, Clinical trial, Financial results, Oncology, Precision medicine